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SUMMARY.-A series of 33 patients with metastatic renal cancer and evidence
of progression of the disease-apart from pulmonary metastases-was treated
with hormones (progestogens in 31 cases, androgens in 2 cases) at the Rotter-
damsch Radio-Therapeutisch Instituut. Complete or partial spontaneous
regression (or non-progression of pulmonary metastases) before hormone
treatment was observed in 8 patients (24%). A favourable subjective response
to hormone treatment was obtained in 12 patients (36%), while a positive
objective response was obtained in 2 (or 3) cases (6-9%).
A favourable response was obtained slightly more frequently in men than
in women. The hormonal effect was not demonstrably related to any of the
following factors: age of the patient, type of progestogen used, the behaviour
ofconcomitantpulmonary metastases, or the presence or absence oftheprimary
growth.
The prognosis was unaffected by hormone therapy, but the 2 year survival
rate was significantly higher in patients that showed signs of spontaneous
regression of pulmonary metastases, as compared with those without these
signs.
IN 1964 Bloomreported 3patients with metastatic renal cancer whoresponded
favourably to hormone treatment with either progestogens or androgens. Subse-
quently other authors (Bloom, 1967; Samuels, Sullivan and Howe, 1968; Paine,
Wright and Ellis, 1970) added further bormonal successes to the literature.
In the Rotterdamsch Radio-Therapeutisch Instituut it has been the rule to
treat bone and soft tissue metastases of renal cancer with radiotherapy, to which
they usually respond with regression and alleviation of pain. According to our
experience haematogenous pulmonary metastases often remain stationary or
regress, partially or completely; only exceptionally do they contribute to local
distress or general deterioration. Therefore they were only occasionally treated
by high-voltage irradiation. After the radio-therapeutic possibilities were ex-
hausted, hormone treatment was applied in patients with extrapulmonary meta-
stases according to the criteria discussed below; haematogenous pulmonary
metastases in themselves were never a reason for staiting hormone treatment.
MATERIAL AND METHODS
Between 1966 and 1970 33 patients with metastatic renal cancer received
hormonal treatment in the Rotterdamsch Radio-Therapeutisch Instituut. These
patients comprised 23 men (average age: 56 years) and 10 women (average age: 58 years). The hormone preparations used and their doses are shown in Table 1.Table II illustrates the response to the various hormone preparations: no
obvious differences between them can be noted.
EXPLANATION OF PLATE
FiG. 1A.-Osteolytic metastatic deposit from renal carcinoma in left ileum before hormonal
treatment.
FIG. IB.--Metastatic deposit 9 months after hormonal treatment showing favourable response with dense recalcification.
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TABLE I.-Hormones Adm.ini8tered and D08es
Niagestine (megestrol acetate)
SH582 (nor-progesterone-caproate)
Farlutal (medroxyprogesterone acetate)
Neohombreol (testosterone propionate,
" F.C.L.")
60 mg. per dav, orally
200 mg., 3 times per week, i.m.
50 mg. per day, orally
50 mg., 3 times per week, i.m.
The choice of the progestogen was determined by its availability; Niagestine
(megestrol acetate) was the first to be marketed in Holland. Androgens were
given to 2patients, mainly in order toimprove thegeneral condition ofthepatient.
Hormone treatment was restricted either topatients withevidentlyprogressive
disease who were unsuitablefor, or nolongerresponding toradiotherapy(haemato-
genouspulmonary metastases wereignored) or topatients in whom the metastases
were clinically unaltered but the general condition was deteriorating, with
increasing subjective malaise. It was discontinued after 4-6 weeks ifthe measur-
able metastases or thepattern ofgeneral deterioration weremanifestlyprogressive,
or after 3 months if no convincinglv favourable response was obtained. The
objective response was considered favourable if the measurable metastases
became smaller or if recalcification was noted in bone metastases (Fig. 1A, B).
A positive subjective response was assumed if the patient stated clearly that he
felt considerably better
" after the start of the hormone treatment.
]RESULTS
A favourable response was usually detected between 2 and 6 weeks. In the
3 patients in whom objective regression occurred, this effect lasted 11, 6, and
3 months; it coincided with subjective iinprovement. The duration of the
positive subjective effect varied from about 1 to 48 months, the average being
9-5 months. (Standard deviation: 3-6 months.)
TABLE II.-Response to Hormone Therapy
Duration of
treatment
(months)
1-11
Favourable response
Subjective Objective
3/13 1/13
(bone metastases)
4/9 1/9
(glandular + pulm. met.)
4/9 1/9 (dubious)
(lymphatic pulmonary spread)
1/2 0/2
12/33 2/33 or 3/33
36% C)-q%
Number
Hormone of cases
Niagestine
SH582
Farlutal .
Neohombreol
Total
13
9
9
1-48
1-6
2
33
1-6
Av.: 4
- 8 months
(standard deviation:
I
- 5 months)BRITISH JOURNAL OF CANCER. Vol. XXV, No. 3.
1A
lo-c.,6 .j
1 B
Werf-Messing and GilseMETASTASES OF RENAL CARCINOMA 425
TABLEIII.-Re,8ponse to Hormonal Treatment in Relation with Nature of
Meta8taticSpread
Favourable response
Number t A
I
of cases Subjective Objective
16 5 (31%) 1 = ?I
(6% or 12%)
9 3 (33%) 0 (%)
Nature of metastases
Bone, soft tissue, glands (no haematogenous pulmonary metastases)
Haematogenous pulmonary metastases-no
spontaneous regression-with metastases
elsewhere (8) and without (1)
Haematogenous pulmonary metastases-stationary or .
regressing spontaneously-combined with other
metastases
Total
8 4 (50%) 1(12%)
2 or 3
6% or 9%)
tffltp 1- k"W /O I 33 12 (360/-)
Table III shows the hormonal effect in relation to 3 groups of patients, viz.
those withextrapulmonary metastases combined withstationary orspontaneously
regressing haematogenous pulmonary metastases, those with extra-pulmonary and progressive pulmonary metastases, and those with extrapulmonary deposits only. No differences in the response to hormone therapy could be demonstrated
between the 3 groups.
TABLE IV.-Sex ofPatient Related to Intprovement after Hormone Treatment
and toSpontaneou8 Regression ofPulmonary MetastaSM
Improvement
Number t A
of cases Subjective Objective
23 11 (48%) 2 (or 3)
9% (or 13%)
10 1 (10%) 0 (0%)
Spontaneous
regression
4 17%
4 40%
Sex ofpatient
Men .
Women
It is evident from Table IV that males responded slightly more favourably than. females; both showed comparable rates of spontaneous regression of
pulmonary metastases before starting the hormone treatment.
The average age of patients who responded and those who failed to respond
was similar. The effect ofthe hormone treatmentappeared to be unrelated to the
absence or presence ofthe primarygrowth (Table V). In no instance were undue
side effects observed, nor was there any obvious causal relationship between
hormone administration and local or general deterioration of the patient.
TABLEV.-Response, to Hormone, Treatment in Relation to Nephrectomy
Favourable response
Number r A
of cases Subjective Objective
5 2 (40%) 0 (0%)
28 . 10 (36%) 2 or 3
(7% or 11%)
No nephrectomy
After nephrectomy
Actuarial survival rates are presented in Graph 1. The prognosis was unin-
fluenced by the subjective response, although the patients showing signs of
spontaneousregression ofpulmonary metastases had asignificantlyhigher 2 years survival rate than those without a tendency towards spontaneous regression.426 B. VAN DER WERF-MESSING AND H. A. VAN GILSE
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Y[G. 2.-Survival in relation to spontaneous regression ofpulmonary metastases.
DISCUSSION
Bloom (1967) reported objective improvement after progestogens and andro-
gens in 8 out of 38 patients (21%); in 3 or more instancesregression ofpulmonary
metastases constituted the improvement. Samuels et al. (1968) obtained a
favourable hormonal effect in 4 out of 23 cases (17%). Three successes were
accounted for by regression of pulmonary metastases. Paine, '"Tright and Ellis
(1970) in a series of 15 cases, reported objective improvement after progestogens in 2 patients with pulmonar metastases and in I with a pleural effusion (200,I) y /0
(Table VI).
TABLF, VI.-Objective Re8pon8e to Hormone Treatment in Several Serie8
Percentage of cases
Number Cases showing showing objective Authors of cases objective improvement improvement
Bloom (1967) 38 Multiple metastases-8 21
(3 pulm. met.)
23 Pulmonary metastases-3
Soft tissue metastasis-1
15 Pulmonary metastases-21
Pleural offusion-1
33 Bone metastases-I
Glandular + pulmonary
metastases-I
Lymphatic intrapulmonary
spread (dubious!)-l
Objective improvement ", if
spontaneous regression had
been attributed to hormones:
7 further cases
Samuels, Sullivan and Howe .
(1968)
Paine, Wright and Ellis
(1970)
Rotterdamsch Radio-
Therapeutisch In-stituut
(1970)
17
20
6-9
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In the R.R.T.I. series of 33 cases, the objective positive response of 6-9%
seems low in comparison with those recorded by other authors. Patients were
not considered eligible for hormone treatment for pulmonary metastases only.
If such cases had been included, complete or partial spontaneous regression or
lack of progression might wronglv have been interpreted as a positive effect of
hormonal treatment; the
" objective favourable response
" would then have been
39% (Table VI). Jenkin (1967) has already pointed out the difficulty of distin-
guishing between spontaneous regression of pulmonary metastases and a good
response to hormoiial treatment.
Spontaneous regressioil of pulmonary metastases niight well reflect the bene-
ficial effect ofautohormonalregulation ofthepatieiit, andtheoretically an external
hormonal booster could enhance this effect. However, in thepresent series neither
the subjective nor the objective response to hormonal treatment appeared to be
related to spontaneous regression (Table 111). Nor did the presence or absence
of the primary growth have any demonstrable relation to the hormonal response
(Table V). The slightly better respoiise in males (Table IV) is in keeping witli
the findings both of Bloom and of Paine. It is possible that in a larger series of
cases some of the above mentioned factors might yet turn out to have some
bearing on the effects of hormonal treatment. The longer survival of patients
with spontaneously regressing pulmonary metastases might reflect a more
favourable general immunological or hormonological state of the patient.
CONCLUSION
Since a course ofradiotherapy usually alleviates pain and produces objective
regression of metastases of renal cancer, therapeutic hormone treatnient should
be resorted toonly when all theradiotherapeutic possibilities have been exhausted.
Hornione therapy offers a modest possibility of palliation without undue side
effects. The value of
" propliylactic
" postnephrectomy hormone administratioii
in patients withoiit demonstrable metastases remains to be proved.
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